Affiliation:
1. Memorial Sloan-Kettering Cancer Center, New York - USA
Abstract
CA 549 is one of several carcinoma associated mucin antigens proposed as a breast cancer tumor marker. In this study, the performance characteristics of the CA 549 assay were validated and the clinical utility of the test was compared with that of other breast cancer markers including CA 15-3, CA M26, CA M29 and carcinoembryonic antigen. The upper limit of normal was established as 15.5 U/ml based on data for 250 control subjects apparently free of disease. Overall, CA 549 had a low negative predictive value (0.51) due to a low sensitivity in the detection of early breast cancer. However, the test had a high positive predictive value (0.93) reflecting a high specificity for the disease. In 56 patients with advanced breast cancer, the sensitivity was 0.71 for CA 549 alone and 0.79-0.84 for CA 549 combined with any of the other markers studied.
Subject
Cancer Research,Clinical Biochemistry,Oncology,Pathology and Forensic Medicine
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Potential diagnostic and prognostic biomarkers for breast cancer: A compiled review;Pathology - Research and Practice;2023-11
2. Avanços Médicos: Marcadores Tumorais Versus Carcinoma de Mama;Revista Brasileira de Cancerologia;2023-06-02
3. Early Biomarkers in Breast Cancer;Noninvasive Molecular Markers in Gynecologic Cancers;2015-01-08
4. Oncology Biomarkers;General and Applied Toxicology;2009-12-15
5. Genomic and proteomic biomarkers for cancer: A multitude of opportunities;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2009-12